In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve ...

Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation.

Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding events than rivaroxaban in patients with atrial fibrillation at moderate-to-high risk ...

John Friend, MD, CEO of Kazia Therapeutics added, "The novelty of the science that Professor Rao has proposed with this dual ...

Researchers have found in a new research that among patients with atrial fibrillation who are at moderate-to-high risk for ...

Discover how abelacimab reduces bleeding risks in AFib patients by effectively lowering free factor XI levels.

A mid-stage trial testing abelacimab from Anthos Therapeutics in patients with atrial fibrillation was stopped early due to ...

Atrial fibrillation (AF) is a common heart condition that affects about one in three people at some point in their lives. It ...

Patients coping with atrial fibrillation and using an experimental blood-thinning drug, abelacimab, experienced significantly fewer bleeding incidents compared to those on standard treatments, a ...

Patients with a common heart rhythm disorder who took an experimental blood-thinning drug had far fewer bleeding episodes ...

Researchers have found that Factor XI inhibitors, such as abelacimab, reduce bleeding risks in atrial fibrillation patients more effectively than standard anticoagulants.

The incidence rate of major or clinically relevant nonmajor bleeding was 3.2, 2.6, and 8.4 events per 100 person-years with 150 mg abelacimab, 90 mg abelacimab, and rivaroxaban, respectively ...